С вашего разрешения мы используем ограниченную аналитику с защитой конфиденциальности, чтобы понять, какие исследовательские сценарии работают. Мы не используем рекламные трекеры или запись сеансов. Этот выбор можно изменить в настройках. Прочитайте Политику конфиденциальности.
Quote this valuation with its source: Fair value, Potential value and the price at analysis.
FAQ
ILMN — frequently asked questions
Is Illumina, Inc. overvalued?
In our latest published analysis dated 2026-10-22, ILMN looks meaningfully overvalued. The price recorded at analysis is 259 USD versus our fair value of 120 USD; the high endpoint is presented separately as potential value of 147 USD. That implies roughly 53.9% downside to fair value at that date.
Our latest published report, analyzed 2026-10-22, gives ILMN a fair value of 120 USD and a potential value of 147 USD. The conclusion is triangulated across multiple valuation models and weighted by reliability for Illumina, Inc.'s archetype; it is a dated research output, not a live price.
Should I buy ILMN now?
Our latest published rating for ILMN, analyzed 2026-10-22, is Sell. Illumina, Inc. looks meaningfully overvalued at the analysis-date price of 259 USD versus fair value of 120 USD; potential value is 147 USD. This is research for educational purposes, not personalized investment advice.
What are the biggest risks for ILMN?
The dedicated bear-case section in our report analyzed 2026-10-22 documents Illumina, Inc.'s material risks, evidence, thresholds, and thesis-invalidation conditions. Scenario-specific explanations remain in that section so the report does not repeat or decontextualize them elsewhere.
What is ILMN's rating?
Our latest published rating for ILMN, analyzed 2026-10-22, is Sell, with a published moat assessment of 9/10 (Wide). It reflects our fair value of 120 USD, the potential value of 147 USD, and the price recorded at analysis (259 USD).
Этот отчёт ещё не переведён. Обновите страницу через несколько минут, когда очередь переводов его обработает.
§1 Краткое резюмеEN
Ответ за 30 секундSell
Цена и стоимость
Цена
$259.19
Справедливая стоимость
$119.53
Потенциальная стоимость
$146.73
На дату
2026-10-22
Почему сценарий может сработать
Accelerated clinical diagnostic adoption in oncology minimal residual disease (MRD) testing and whole-genome rare disease screening driving NovaSeq X consumable pull-through well above mid-teens expectations.
Что изменит нашу оценку
A prolonged contraction in academic and government research funding combined with persistent high-bandwidth memory component cost inflation.
Illumina is rated Sell with Fair value of $119.53 compared to $259.19, reflecting -53.9% upside.
Illumina commands a Wide economic moat underpinned by massive clinical switching costs and proprietary sequencing-by-synthesis (SBS) intellectual property. Clinical customers are expanding their installed base of NovaSeq X instruments to support expanding clinical test volumes, driving mid-teens clinical consumables growth guidance for FY2026. Following the divestiture of GRAIL, core operating profitability has rebounded, with GAAP operating income reaching $807M in FY2025 and FY2026 non-GAAP operating margin guided to 23.4%-23.6%. of $1,079M in FY2025 yielded $931M in .
Despite these solid operational fundamentals, the stock exhibits an extreme valuation disconnect. At $259.19, ILMN trades at 40.32x forward earnings, pricing in aggressive multi-year growth acceleration that conflicts with low single-digit sequencing instrument growth and mid-to-high single-digit contraction in research consumables. Reverse DCF analysis demonstrates that current pricing requires a 19.44% 10-year earnings CAGR, far above the realistic 11.04% rate supported by business economics. Our multi-model intrinsic fair value midpoint of $119.53 sits 46.38% below the present-value equivalent of the consensus 12-month target of $222.94, establishing a clear Sell recommendation.2,4,5
High Customer Switching Costs in Clinical Workflows
Clinical diagnostic customers develop validated laboratory developed tests (LDTs) and IVD workflows around Illumina hardware and proprietary sequencing chemistry, creating immense switching costs and multi-year consumable pull-through.5
Proprietary Intellectual Property and Sequencing Chemistry
Illumina maintains extensive intellectual property protecting its proprietary sequencing-by-synthesis (SBS) technology and optical detection systems, supporting consolidated gross profit of $2,870M on $4,343M revenue (66.1% gross margin) in FY2025.5,7
Installed Base Scale and Ecosystem Integration
A massive global installed base of NovaSeq X and benchtop instruments creates strong platform network effects and workflow standardization across major hospital systems and commercial laboratories.5
Рекомендация дома
Sell. Illumina is an exceptional business trading at a speculative valuation. While the company's Wide economic moat and clinical sequencing expansion remain fully intact, the market price of $259.19 trades at a 116.84% premium to our intrinsic fair value midpoint of $119.53. With the equity discounting an aggressive 19.44% multi-year growth rate against management's 6.5% modeled FY2026 growth, the risk/reward profile is deeply skewed to the downside.1
Обзор компании
Illumina, Inc. is a global provider of life science tools and integrated systems for large-scale analysis of genetic variation and biological function. The company develops, manufactures, and commercializes next-generation sequencing (NGS) and array-based technologies serving customers across clinical, academic, and applied end-markets. Key platforms include the high-throughput NovaSeq X series, alongside mid-throughput NextSeq and benchtop MiSeq instruments.
In FY2025, Illumina generated $4,343M in consolidated net revenue. Geographically, the business is anchored by the United States, which contributed $2,243M (51.6% of sales), within the broader Americas region at $2,406M (55.4%). Europe contributed $1,264M (29.1%), Asia-Pacific, Middle East, and Africa (APMEA) delivered $430M (9.9%), and Greater China generated $243M (5.6%). Following the completed spin-off of GRAIL, Illumina operates as a streamlined pure-play genomic sequencing platform.
§2 Медвежий сценарийEN
A compounding downside stress test models simultaneous academic grant freezes, persistent high-bandwidth memory component inflation, and regulatory displacement in Greater China. In this environment, research consumables contract by double digits, operating margins compress toward 21.0%, and total top-line revenue growth stalls below 4.0%. Under these operating pressures, intrinsic valuation contracts toward the downside valuation floor of $91.84. At $259.19, long investors face severe, unhedged downside vulnerability without an adequate margin of safety.
Under the Bear scenario, persistent academic research budget contractions suppress consumable utilization while high-bandwidth memory input inflation and China revenue contraction constrain operating margins to approximately 21.0%. Five-year revenue CAGR slows toward low single digits as clinical adoption fails to fully offset broader research lab headwinds.
Как может разрушиться эта теза
Persistent Memory Cost Inflation and Research Consumable Margin Compression
Unanticipated spikes in high-bandwidth memory and freight expenses combined with mid-to-high single-digit declines in research consumables compress operating margin below 20.5% (a 300 bps shock against the 23.5% baseline guidance), driving an 18.5% fair value impairment.5
FV impact
0%
Operating margin 3 points lower throughout
Trigger
Within 12 months
Сигналы раннего предупреждения для мониторинга
Пять событий, которые ослабят наш инвестиционный тезис.
01
Research and Applied Consumables Growth
Signals deep structural funding contraction in academic and government laboratories that overwhelms clinical expansion.
Текущее значение:Mid-to-high single-digit decline in FY2026
Предупреждение, еслиDecline exceeding 12% YoY for two consecutive quarters
Illumina possesses a Wide economic moat anchored by massive switching costs and proprietary intellectual property in next-generation sequencing (NGS). In clinical diagnostic settings—including oncology profiling, non-invasive prenatal testing (NIPT), and rare disease genetics—customers validate laboratory procedures, regulatory compliance filings, and bioinformatics pipelines specifically around Illumina's sequencing-by-synthesis technology. Replacing an installed sequencing fleet incurs immense re-validation costs, regulatory re-filing burdens, and retraining hurdles, locking in customers for the multi-year lifecycle of each instrument.
This customer captivity transforms instrument placements into recurring, high-margin reagent consumption. Product gross profit was $2,870M on $4,343M in FY2025 revenue, and non-GAAP gross margin reached 68.2% in Q2 2026. In clinical end-markets, management projects mid-teens revenue growth for FY2026, demonstrating that high-value diagnostic applications continue to deepen Illumina's moat outside of Greater China, where regulatory sanctions have restricted market access ($243M in FY2025 revenue).
Экономическая прибыль
Illumina generates sustainable economic profit with an ROIC of 15.08% exceeding its weighted average cost of capital (WACC) of 9.90% and cost of equity of 10.26% by 518 bps. Following the divestment of GRAIL, GAAP operating income rebounded to $807M in FY2025 on $4,343M in consolidated revenue, supporting excess returns over a 15-year competitive advantage horizon.2,7
9/ 10
Wide
Sources of advantage
01High Customer Switching Costs in Clinical Workflows — Clinical diagnostic customers develop validated laboratory developed tests (LDTs) and IVD workflows around Illumina hardware and proprietary sequencing chemistry, creating immense switching costs and multi-year consumable pull-through.Wide
02Proprietary Intellectual Property and Sequencing Chemistry — Illumina maintains extensive intellectual property protecting its proprietary sequencing-by-synthesis (SBS) technology and optical detection systems, supporting consolidated gross profit of $2,870M on $4,343M revenue (66.1% gross margin) in FY2025.
Известные угрозы для рва
Угроза
Серьёзность
Временная шкала
Митигация
Academic and Government Research Laboratory Funding Contraction
medium
12-18 months
Expanding commercial exposure in clinical oncology and genetic disease diagnostics, where demand is nondiscretionary and growing mid-teens.5
The highlighted cell is Fair value when every assumption sits at its base level ($119.53). Each row and column shows what Fair value becomes when one assumption moves.
The modal base path reflects management's FY2026 guidance for reported revenue and operating margin. Clinical consumables expansion at mid-teens offsets mid-to-high single-digit research declines. This trajectory generates Fair value of $119.53, implying -53.9% return relative to $259.19.5
Maintain Sell; Maintain capital discipline and use any post-earnings liquidity strength to continue liquidating or trimming overvalued equity positions.
Even a material quarterly beat does not resolve the substantial valuation disconnect where the stock trades at 40.32x forward earnings and a 116.84% premium to intrinsic fair value.
По плану
Maintain Sell; Maintain existing risk management constraints and deploy zero fresh capital into the equity.
Триггер: Quarterly revenue within $1.14B-$1.16B and non-GAAP diluted EPS within $1.33-$1.385
Meeting guidance confirms the modeled financial path ($4.60B-$4.64B revenue, 23.4%-23.6% operating margin) without bridging the valuation gulf to intrinsic worth of $119.53.
Ниже плана
Maintain Sell; Re-evaluate downside stop-loss thresholds and ensure no unhedged long exposure remains in institutional portfolios.
High earnings quality. FY2025 operating cash flow of $1,079M represented 126.9% of GAAP net income of $850M, generating $931M in free cash flow. Non-GAAP adjustments in Q2 2026 were routine and clean, consisting primarily of acquisition-related intangible asset amortization ($18M) and ERP transformation implementation expenses ($4M).6,7
Динамика прогнозов
Consensus revisions remained flat across FY2026 and FY2027 following the Q2 2026 financial release. Sell-side consensus expects FY2026 revenue of $4,624M and diluted EPS of $5.36, and FY2027 revenue of $4,923M and diluted EPS of $6.13.1
Метрики для отслеживания перед отчётом
01
Метрика:
Clinical Sequencing Consumables Growth
ТекущееManagement projects mid-teens growth in clinical consumables for FY2026.
Почему это важно
Tests whether clinical oncology and rare disease testing can outpace research lab headwinds.5
Illumina exhibits strong cash generation. FY2025 operating cash flow reached $1,079M, funding $148M in capital expenditures to generate $931M in free cash flow. In Q2 2026, cash flow from operations was $201M and free cash flow was $162M. Operating cash flow conversion consistently exceeds 100% of GAAP net income ($850M in FY2025), validating the high cash quality of core sequencing operations.6,7
Распределение капитала
Illumina exercises conservative capital allocation following the GRAIL separation. Balance sheet cash and short-term investments totaled $1,168M ($1,040M cash plus $128M short-term investments) as of June 28, 2026, against total term debt of $2,527M ($500M current portion plus $1,491M and accrued liabilities). remain modest at $148M in FY2025 and $39M in Q2 2026, absorbing approximately 18% of NOPAT and leaving ample organic for balance sheet de-leveraging.
GAAP operating profitability has recovered to $807M in FY2025 from negative levels in FY2024 (-19.05% margin), with non-GAAP operating margin guided to expand to 23.4%-23.6% in FY2026. ROIC of 15.08% confirms robust economic value creation above the cost of capital.
Product revenue reached $982M in Q2 2026, driven by mid-single-digit sequencing consumables growth while sequencing instruments grew low single digits.
Expanding consumables mix elevates non-GAAP gross margin to 68.2% and reduces top-line cyclicality.
Структура отчёта о прибылях и убыткахКак масштаб бизнеса преобразуется в отчетную прибыль.30 июн. 2026 г.
StockMarketAgent.AI
Выручка1,2 млрд $Себестоимость выручки−389 млн $Валовая прибыль770 млн $Операционные расходы−525 млн $Операционная прибыль245 млн $Внереализационные статьи и налоги−38 млн $Чистая прибыль207 млн $
Данные финансовой истории
Выручка
1 159 000 000 $
Себестоимость выручки
389 000 000 $
Валовая прибыль
770 000 000 $
Операционные расходы
525 000 000 $
Операционная прибыль
245 000 000 $
Внереализационные статьи и налоги
-38 000 000 $
Чистая прибыль
207 000 000 $
Обзор балансаКак представлены и профинансированы заявленные активы за выбранный период.
StockMarketAgent.AI
Структура активовИсточники финансирования
Активы, всего6,6 млрд $Денежные средства1,4 млрд $Оборотные активы3,3 млрд $Обязательства, всего3,9 млрд $Краткосрочные обязательства1,6 млрд $Акционерный капитал2,7 млрд $
Данные структуры баланса
Активы, всего
6 644 000 000 $
Денежные средства
1 418 000 000 $
Оборотные активы
3 289 000 000 $
Обязательства, всего
3 921 000 000 $
Краткосрочные обязательства
1 585 000 000 $
Акционерный капитал
2 723 000 000 $
Мост денежных потоковКак операционный денежный поток превратился в свободный денежный поток в FY2025.
StockMarketAgent.AI
Сверка операционного денежного потока
Чистая прибыль850 млн $Амортизация+270 млн $Компенсация акциями+275 млн $Прочие операционные корректировки−316 млн $Операционный денежный поток1,1 млрд $
Сверка денежных средств на начало и конец
Денежные средства на начало1,1 млрд $Операционный денежный поток+1,1 млрд $Инвестиционный денежный поток−55 млн $Финансовый денежный поток−744 млн $Влияние обменного курса+11 млн $Денежные средства на конец1,4 млрд $
1,1 млрд $ − 148 млн $Свободный денежный поток 931 млн $
Данные моста денежных потоков
Чистая прибыль
850 000 000 $
Операционный приток
1 395 000 000 $
Амортизация
270 000 000 $
Компенсация акциями
275 000 000 $
Операционный денежный поток
1 079 000 000 $
Операционный отток
316 000 000 $
Доступные денежные средства
2 217 000 000 $
Денежные средства на начало
1 127 000 000 $
Влияние обменного курса
11 000 000 $
Инвестиционный отток
55 000 000 $
Финансовый отток
744 000 000 $
Выкуп акций
742 000 000 $
Чистое погашение долга
5 000 000 $
Денежные средства на конец
1 418 000 000 $
Инвестиционный денежный поток
-55 000 000 $
Финансовый денежный поток
-744 000 000 $
Выручка по операционным сегментамДоля общей выручки за 2024-12-29.
4,4 млрд $Общая выручка
Выручка по операционным сегментамДоля
Core Illumina4,3 млрд $99,1 %−2,4 % г/г
GRAILInc.55 млн $1,3 %−40,9 % г/г
Источник: SEC EDGAR · Подано 2026-02-12 · SEC EDGAR
Данные о структуре выручки: Выручка по операционным сегментам
Выручка по операционным сегментам
Выручка
Доля
г/г
Core Illumina
4,3 млрд $
99,1 %
-2,4 %
GRAILInc.
55 млн $
1,3 %
-40,9 %
Выручка и прибыльКак масштаб бизнеса преобразуется в отчетную прибыль.
Денежные средства и долгДоступная ликвидность относительно общей задолженности.
Генерация денежных средствОперационный денежный поток в сравнении со свободным денежным потоком.
РентабельностьДинамика валовой, операционной и чистой маржи.
Финансовые данные на конкретную дату, использованные в анализе от 2026-10-22.
Illumina, Inc. (ILMN) trades at 40.3x forward earnings against a peer median of 22.4x. Its EV/EBITDA of 38.2x compares with a peer median of 22.4x. The comparison uses 4 peers: IDEXX Laboratories Inc., IQVIA Holdings Inc., Agilent Technologies Inc. and Labcorp Holdings Inc., as of 2026-10-22.
§10 Отрасль и циклEN
Фаза цикла
Contraction
The life sciences tools industry benchmark exhibits disciplined capital intensity, with industry capex-to-revenue at 4.5% and capex-to-depreciation at 0.8. Illumina's capex was $148M on $4,343M revenue (3.41%) in FY2025 against depreciation of $270M (capex/depreciation of 0.55). Capex was $39M in Q2 2026. Industry capacity and supplier lead-time data are unavailable, meaning this capital cycle assessment is demand-led and evidence-limited.7
Бычий цикл
In an expansionary upcycle, synchronized recovery in biopharma R&D funding and academic research grants accelerates NovaSeq X placements above low single digits, driving double-digit expansion across clinical and research sequencing consumables.
Медвежий цикл
In a severe tools downcycle, prolonged academic and government grant constraints deepen research consumable contractions beyond mid-to-high single digits, clinical instrument purchasing approvals face hospital budget scrutiny, and consolidated revenue growth decelerates toward low single digits.
Долгосрочные тренды
Тренд
Влияние
Примечание
Clinical Genomics and Multiomics Expansion
positive
Next-generation sequencing is transitioning into standard-of-care clinical diagnostic protocols across oncology and rare disease, supporting mid-teens clinical market growth.
Academic and Government Research Funding Constraints
negative
Austerity in government research grants and university endowments drives mid-to-high single-digit declines in research and applied consumables.
Geopolitical Bifurcation in Analytical Instrumentation
Позиционирование
Illumina maintains a highly defended demand position in clinical oncology and genetic testing, anchored by $2,243M in United States revenue (51.6% of FY2025 net sales). This non-discretionary clinical diagnostic base buffers consolidated revenue against biopharma capex pauses and academic funding austerity, allowing Illumina to navigate industry capital cycles more resiliently than pure-play research tools peers.8
§11 Управление позициейEN
Размер позиции
0%
A 0% allocation is warranted due to extreme valuation excess. The equity trades at $259.19, representing a 116.84% premium to our intrinsic fair value midpoint of $119.53 and a 76.64% premium even to the high-end Bull case of $146.73. Risk/reward is entirely uncompensated for long investors.4
Риск
Capital preservation is paramount. Given the 116.84% premium to intrinsic fair value and forward P/E of 40.32x, long exposure entails severe downside vulnerability if quarterly revenue or operating marginguidance falls short. Portfolios should reallocate capital to life sciences tools peers offering realistic valuations.
Транши входа
Уровень
Действие
Почему
$119.53
Valuation review checkpoint
Aligns price with intrinsic fair value midpoint of $119.53, eliminating the speculative valuation premium.
At 40.32x forward earnings and a 116.84% premium to intrinsic fair value, the equity prices in a 19.44% 10-year growth rate that is detached from management guidance and market reality.2,4
Fundamental Quality vs Price
Avoid
Although Illumina possesses a Wide moat and robust free cash flow generation ($931M in FY2025), high business quality cannot justify paying over double the business's intrinsic worth.6
Risk/Reward Asymmetry
Avoid
Even under an optimistic Bull case where clinical growth accelerates and operating margins reach 26%, fair value reaches only $146.73, which remains 43.4% below current trading prices of $259.19.4
§14 Итоговая рекомендацияEN
Действие
Продавать
We recommend a Sell rating on Illumina, Inc. with Fair value of $119.53 against the share price of $259.19, reflecting -53.9% upside. While Illumina commands a wide economic moat in clinical genetic sequencing, shares trade well above intrinsic worth.
The stock trades at 40.32x forward earnings, pricing in aggressive growth acceleration that conflicts with low single-digit instrument placement growth and research consumables contraction. Investors should exit long positions and reallocate capital elsewhere.
§15Your notes
Capture your own thesis, position size, and follow-up questions. Stays on this device, only you can see it.
Private notes
Visible only to you. Synced to this device.
0 chars
Sources
The records this analysis drew on, as they stood when it was run.
Not every cited input appears here: internal calculations and intermediate model outputs have no external record, and some citations could not be matched to one.
Multiple De-Rating on Structural Deceleration in Academic Sequencing
If FY2027 revenue fails to achieve high single-digit growth due to prolonged academic lab funding contraction, market expectations de-rate the terminal P/E multiple by 20% from 24.0x to 19.2x, aligning valuation with peers like IQVIA at 19.2x forward P/E, generating a 20.0% fair value contraction.5
FV impact
-8.5%
Terminal multiple 20% lower
Trigger
Within 18 months
Clinical Adoption Stagnation and Severe Research Lab Disinvestment
Sequencing instruments growth stagnates near low single digits and research consumables continue contracting, driving 5-year revenue growth 500 bps below the modeled 6.5%-7.5% trajectory, triggering a 27.5% fair value decline.1,5
FV impact
-2.4%
Revenue and EPS growth 5 points lower for five years
Trigger
Within 24 months
Indicates failure to offset component inflation in memory and GPUs and severe loss of operating expense leverage.
03Installed Base Scale and Ecosystem Integration — A massive global installed base of NovaSeq X and benchtop instruments creates strong platform network effects and workflow standardization across major hospital systems and commercial laboratories.Moderate
Geopolitical Sanctions and Domestic Substitution in Greater China
medium
Ongoing
Diversifying geographic mix toward the Americas ($2,406M FY2025) and Europe ($1,264M FY2025), isolating China to 5.6% ($243M) of total sales.8
Hardware Input Cost Spikes in Memory and GPUs
low
6-12 months
Securing forward component inventory buffers and driving manufacturing operational efficiencies.5
In the Bull case, clinical sequencing expands rapidly across oncology and rare disease diagnostics, driving mid-teens clinical consumables growth and enabling FY2027 revenue to reach high single digits. Operating margins expand via high consumable pull-through, supporting Potential value of $146.73. Notably, even this optimistic outcome remains well below $259.19.5
Почему это важно
Confirms whether operational discipline offsets memory and freight cost inflation.5
03
Метрика:
NovaSeq X Instrument Placement Pace
ТекущееFull-year sequencing instrument growth guided to low single digits.
Почему это важно
Active instrument additions drive the high-margin consumable replenishment stream in subsequent years.5
04
Метрика:
Research & Applied Consumables Run-Rate
ТекущееGuided to decline mid to high single digits in FY2026.
Почему это важно
Measures the extent of academic and government lab funding contraction.5
05
Метрика:
US Clinical Demand Concentration
ТекущееGenerated $2,243M in FY2025, or 51.6% of consolidated revenue.
Почему это важно
US diagnostic adoption provides the primary demand anchor insulating against China geopolitical headwinds.8
